
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is a commercial-stage biotechnology company with a diverse pipeline of drug candidates in various therapeutic areas. Their main product, KIMMTRAK, is currently the standard of care treatment for a rare type of melanoma, and the company's other drug candidates show promise in treating various oncology, infectious, and autoimmune diseases. Additionally, their use of advanced technology and strong partnerships position them for future success and potential value creation. Although there are risks involved in the clinical development and commercialization process, Immunocore's current market presence and potential for growth make them a promising investment opportunity.
Bears say
Immunocore Holdings is facing significant risk in its stock outlook due to high competition in the biotechnology industry and its lack of diversity in its product pipeline. With only one commercial product, KIMMTRAK, and a pipeline still in early stages of development, the company is heavily dependent on the success of its current product. Additionally, with a track record of negative earnings and decreasing cash flows, the company's financial health and potential for future growth seem uncertain.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares